Fosbretabulin for the treatment of anaplastic thyroid cancer

被引：1
|
作者：
Granata, Roberta [1 ]
Locati, Laura D. [1 ]
Licitra, Lisa [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Milan, Italy
来源：
FUTURE ONCOLOGY | 2014年 / 10卷 / 13期
关键词：
anaplastic thyroid cancer; fosbretabulin; tubulin-binding agent; COMBRETASTATIN A-4 PHOSPHATE; A4; PHOSPHATE; PHASE-II; TRIAL; AGENT; PATHOGENESIS; MANAGEMENT; CARCINOMA; SCHEDULE;
D O I：
10.2217/FON.14.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
引用
收藏
页码：2015 / 2021
页数：7
相关论文
共 50 条
  • [31] Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
    Gentile, Daniela
    Orlandi, Paola
    Banchi, Marta
    Bocci, Guido
    MEDICAL ONCOLOGY, 2020, 37 (03)
  • [32] Recent advances in precision medicine for the treatment of anaplastic thyroid cancer
    Ferrari, Silvia Martina
    Fallahi, Poupak
    La Motta, Concettina
    Elia, Giusy
    Ragusa, Francesca
    Ruffilli, Ilaria
    Patrizio, Armando
    Baldini, Enke
    Ulisse, Salvatore
    Antonelli, Alessandro
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (01): : 37 - 49
  • [33] Survival Benefit of Intervention Treatment in Advanced Anaplastic Thyroid Cancer
    Kasemsiri, Pornthep
    Chaisakgreenon, Pimpika
    Vatanasapt, Patravoot
    Laohasiriwong, Supawan
    Teeramatwanich, Watchareeporn
    Thongrong, Cattleya
    Ratanaanekchai, Teeraporn
    Suetrong, Surapol
    INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2021, 2021
  • [34] Multimodality treatment of anaplastic thyroid cancer with nearly resolved effect
    Tseng, Yu-Ting
    Chang, Tien-Chun
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (09) : 897 - 898
  • [35] Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
    Guerra, Anna
    Di Crescenzo, Vincenzo
    Garzi, Alfredo
    Cinelli, Mariapia
    Carlomagno, Chiara
    Tonacchera, Massimo
    Zeppa, Pio
    Vitale, Mario
    BMC SURGERY, 2013, 13
  • [36] Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study
    Iwasaki, Hiroyuki
    Yamazaki, Haruhiko
    Takasaki, Hirotaka
    Suganuma, Nobuyasu
    Nakayama, Hirotaka
    Toda, Soji
    Masudo, Katsuhiko
    ONCOLOGY LETTERS, 2018, 16 (06) : 7271 - 7277
  • [37] Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer
    Sekihara, Kazumasa
    Himuro, Hidetomo
    Toda, Soji
    Saito, Nao
    Hirayama, Ryoichi
    Suganuma, Nobuyasu
    Sasada, Tetsuro
    Hoshino, Daisuke
    BIOMEDICINES, 2024, 12 (06)
  • [38] Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer
    De Andrade, James P.
    Lorenzen, Allison W.
    Wu, Vincent T.
    Bogachek, Maria V.
    Park, Jung M.
    Gu, Vivian W.
    Sevenich, Claire M.
    Cassady, Victoria C.
    Beck, Anna C.
    Kulak, Mikhail V.
    Robinson, Robert A.
    Lal, Geeta
    Weigel, Ronald J.
    ONCOTARGET, 2017, 8 (70) : 114801 - 114815
  • [39] Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
    Daniela Gentile
    Paola Orlandi
    Marta Banchi
    Guido Bocci
    Medical Oncology, 2020, 37
  • [40] RESULTS OF SURGICAL-TREATMENT OF ANAPLASTIC THYROID-CANCER
    HOLLINGER, A
    HODEL, T
    HEDINGER, C
    LARGIADER, F
    HELVETICA CHIRURGICA ACTA, 1985, 52 (02) : 381 - 382
12345